23 June 2025
23 June 2025
Revenue for Madrigal鈥檚 Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.
Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and human-centric in vitro models.
An EMA committee has recommended approval of Alvotech鈥檚 AVT06, a biosimilar to Bayer鈥檚 blockbuster ophthalmology drug Eylea.
The approval is supported by the randomised Phase III NATALEE study.
The approval is supported by the outcomes from the ADHERE trial.
AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications.
The parties will focus on streamlining regulatory procedures to enhance manufacturing readiness.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
